Izamby

Denosumab, the active ingredient in Izamby, is a monoclonal antibody presented as a subcutaneous injection for the treatment of osteoporosis in postmenopausal women, bone loss in men receiving androgen deprivation therapy, and skeletal‑related events in patients with bone metastases. GNH USA supplies Izamby as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Izamby (denosumab) acts on the RANK/RANKL pathway to modify bone remodeling in several clinical settings. - Postmenopausal osteoporosis: reduces the risk of vertebral, hip and non‑vertebral fractures in women at high fracture risk. - Prostate cancer bone loss: mitigates bone mineral density loss in men undergoing androgen deprivation therapy. - Bone metastases: prevents skeletal‑related events such as pathological fractures, spinal cord compression and the need for radiation or surgery in patients with solid‑tumour bone metastases.

Common Side Effects: - Injection site reactions: pain, redness or swelling at the injection site. - Hypocalcemia: low blood calcium levels, especially in patients with vitamin D deficiency. - Musculoskeletal pain: joint or muscle discomfort. - Skin rash: mild erythema or pruritus. - Upper respiratory infection: nasopharyngitis or sinusitis. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: exposed bone in the maxillofacial region. - Atypical femur fracture: low‑energy fracture of the femoral shaft. - Severe hypersensitivity: anaphylaxis or angioedema. - Severe hypocalcemia: symptomatic calcium depletion. - Serious infections: opportunistic or severe bacterial infections. - Dermatologic reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following precautions: - Renal function: assess calcium and vitamin D status and monitor renal function. - Dental health: obtain a dental examination and address any infections before treatment. - Calcium/Vitamin D supplementation: ensure adequate intake to reduce hypocalcemia risk. - History of hypersensitivity: avoid use in patients with prior severe reactions to denosumab. - Pregnancy and lactation: use only if clearly needed; limited safety data are available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab may interact with several medications that affect calcium balance or immune function. Major Interactions (Avoid): - Concurrent high‑dose calcium supplements: may blunt therapeutic effect. - Other bone‑targeting agents (e.g., bisphosphonates): increase risk of hypocalcemia. - Immunosuppressants: heightened infection risk. - Live vaccines: contraindicated during treatment. - Severe renal impairment drugs: may exacerbate calcium disturbances. Moderate Interactions (Monitor Closely): - Corticosteroids: may increase hypocalcemia risk. - Hormone therapy (e.g., estrogen, testosterone): may alter bone turnover. - Anticonvulsants inducing hepatic enzymes: could affect vitamin D metabolism. - Diuretics (thiazides): may influence calcium levels. - Antacids containing aluminum or magnesium: may affect absorption of supplemental calcium.